New survival standards for advanced melanoma.

Spain, Lavinia; Larkin, James; Turajlic, Samra

Spain, Lavinia; Larkin, James; Turajlic, Samra.

Afiliação

Spain L; Skin and Renal Unit, Royal Marsden NHS Foundation Trust, London, UK.
Larkin J; Department of Medical Oncology, Eastern Health, Melbourne, VIC, Australia.
Turajlic S; Eastern Health Clinical School, Monash University, Melbourne, VIC, Australia.

Br J Cancer ; 122(9): 1275-1276, 2020 04.

Article em En | MEDLINE | ID: mdl-32063602

ABSTRACT

ABSTRACT

The expectation for survival in patients with advanced melanoma now exceeds 50% at 5 years in patients treated with first-line combination ipilimumab and nivolumab, despite this regimen being associated with substantial toxicity. We discuss the latest updates from the Checkmate-067 study, framing the role of this combination in practice today.

Assuntos

Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico; Ipilimumab/uso terapêutico; Melanoma/tratamento farmacológico; Nivolumabe/uso terapêutico; Humanos; Melanoma/epidemiologia; Intervalo Livre de Progressão

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Ipilimumab / Nivolumabe / Melanoma Limite: Humans Idioma: En Revista: Br J Cancer Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google